AP3464A - The use of an l3 and/or l5 source as a vaccine or as a vaccine or as a diagnostic for a parasitic disease - Google Patents

The use of an l3 and/or l5 source as a vaccine or as a vaccine or as a diagnostic for a parasitic disease

Info

Publication number
AP3464A
AP3464A AP2012006275A AP2012006275A AP3464A AP 3464 A AP3464 A AP 3464A AP 2012006275 A AP2012006275 A AP 2012006275A AP 2012006275 A AP2012006275 A AP 2012006275A AP 3464 A AP3464 A AP 3464A
Authority
AP
ARIPO
Prior art keywords
vaccine
diagnostic
source
parasitic disease
parasitic
Prior art date
Application number
AP2012006275A
Other languages
English (en)
Other versions
AP2012006275A0 (en
Inventor
Garcia Laura Ramirez
Carlos Alonso-Bedate
Manuel Soto-Alvarez
Original Assignee
Leti Sl Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leti Sl Lab filed Critical Leti Sl Lab
Publication of AP2012006275A0 publication Critical patent/AP2012006275A0/xx
Application granted granted Critical
Publication of AP3464A publication Critical patent/AP3464A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AP2012006275A 2009-11-13 2010-11-12 The use of an l3 and/or l5 source as a vaccine or as a vaccine or as a diagnostic for a parasitic disease AP3464A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26102009P 2009-11-13 2009-11-13
EP09175929 2009-11-13
PCT/EP2010/067380 WO2011058137A1 (en) 2009-11-13 2010-11-12 The use of an l3 and/or l5 source as a vaccine or as a diagnostic for a parasitic disease

Publications (2)

Publication Number Publication Date
AP2012006275A0 AP2012006275A0 (en) 2012-06-30
AP3464A true AP3464A (en) 2015-11-30

Family

ID=42060726

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006275A AP3464A (en) 2009-11-13 2010-11-12 The use of an l3 and/or l5 source as a vaccine or as a vaccine or as a diagnostic for a parasitic disease

Country Status (26)

Country Link
US (1) US10604551B2 (es)
EP (2) EP2499158B1 (es)
JP (1) JP5875987B2 (es)
KR (1) KR101881947B1 (es)
CN (2) CN107551264B (es)
AP (1) AP3464A (es)
AR (1) AR080621A1 (es)
AU (1) AU2010317962B2 (es)
BR (1) BR112012011395B1 (es)
CA (1) CA2780740C (es)
CO (1) CO6551684A2 (es)
CY (1) CY1118402T1 (es)
EA (1) EA022221B1 (es)
EC (1) ECSP12011951A (es)
ES (1) ES2612786T3 (es)
HR (1) HRP20170176T1 (es)
IL (1) IL219770A (es)
MA (1) MA33813B1 (es)
MX (1) MX341066B (es)
PE (1) PE20121553A1 (es)
PH (1) PH12012500942A1 (es)
PT (1) PT2499158T (es)
SA (1) SA110310855B1 (es)
TN (1) TN2012000217A1 (es)
WO (1) WO2011058137A1 (es)
ZA (1) ZA201203516B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
US9187751B2 (en) * 2010-11-10 2015-11-17 Laboratorios Leti, S.L. Adjuvant
SG194850A1 (en) * 2011-05-09 2013-12-30 Leti Sl Lab Molecule for treating an inflammatory disorder
ES2681227T3 (es) * 2013-07-02 2018-09-12 Institut De Recherche Pour Le Développement Péptidos y métodos para la detección de la leishmaniasis
US10973897B2 (en) * 2016-04-14 2021-04-13 Peptcell Limited Chagas antigens and antibodies and compositions, methods and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
WO2000039298A1 (en) 1998-12-23 2000-07-06 C.B.F. Leti S.A. Chimeric gene encoding the antigenic determinants of four proteins of l. infantum
FR2826018B1 (fr) * 2001-06-18 2005-01-07 Pasteur Institut Tunis Gene associe a la virulence du parasite leishmania
US20050250716A1 (en) 2001-12-07 2005-11-10 Intercell Ag Immunostimulatory oligodeoxynucleotides
DK1618128T3 (da) 2003-04-23 2010-10-18 Max Planck Gesellschaft Tuberkulosevaccine med forbedret effektivitet
KR100992646B1 (ko) 2003-07-09 2010-11-05 제이에스알 가부시끼가이샤 파장판
RS52507B (sr) 2003-11-05 2013-04-30 Laboratorios Leti S.L. Primena specifičnih histona za lečenje parazitnih bolesti
CA2540736A1 (en) * 2005-04-08 2006-10-08 Institut Pasteur Polypeptides of leishmania major and polynucleotides encoding same and vaccinal, therapeutical and diagnostic applications thereof
CN101466831A (zh) * 2006-04-10 2009-06-24 传染病研究所有限公司 用于诊断和治疗利什曼病的化合物和方法
US8916168B2 (en) * 2007-07-13 2014-12-23 Infectious Disease Research Institute Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis
AP3007A (en) * 2008-01-18 2014-10-31 Leti Sl Lab Vaccine comprising a ribosomal protein extract (RPE) and optionally a thi-promoting adjuvant
AP3516A (en) * 2009-07-13 2016-01-11 Leti Sl Lab Diagnosis of a parasitic disease such as leishmaniasis using ribosomal protein extract (rpe)
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [Online] 30 August 2005, "SubName: Full=60S ribosomal protein L5, putative;", retrieved from EBI accession no. UNIPROT:Q4FWT2 Database accession no. Q4FWT2 ; & SCIENCE), vol. 309, no. 5733, July 2005, pages 436-442, 416 *
IBORRA S ET AL: MICROBES AND INFECTION, ELSEVIER, PARIS, FR, vol. 10, no. 10-11, 1 August 2008, pages 1133- 1141 *
SOTO MANUEL ET AL: "Multicomponent chimeric antigen for bserodiagnosis of canine visceral leishmaniasis", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 36, no. 1, January 1998, pages 58-63, *

Also Published As

Publication number Publication date
BR112012011395A2 (pt) 2020-09-01
CN102712684A (zh) 2012-10-03
AR080621A1 (es) 2012-04-25
US10604551B2 (en) 2020-03-31
JP5875987B2 (ja) 2016-03-02
KR20120104567A (ko) 2012-09-21
ES2612786T3 (es) 2017-05-18
EA022221B1 (ru) 2015-11-30
MX2012005522A (es) 2012-09-28
ECSP12011951A (es) 2012-07-31
PT2499158T (pt) 2017-01-24
IL219770A (en) 2017-10-31
US20120263746A1 (en) 2012-10-18
EP2499158A1 (en) 2012-09-19
CN107551264A (zh) 2018-01-09
AU2010317962B2 (en) 2014-09-18
MA33813B1 (fr) 2012-12-03
TN2012000217A1 (en) 2013-12-12
IL219770A0 (en) 2012-07-31
CY1118402T1 (el) 2017-06-28
EP2499158B1 (en) 2016-11-02
PE20121553A1 (es) 2012-12-13
JP2013510823A (ja) 2013-03-28
MX341066B (es) 2016-08-05
WO2011058137A1 (en) 2011-05-19
PH12012500942A1 (en) 2013-01-07
CN107551264B (zh) 2021-05-11
AU2010317962A1 (en) 2012-06-21
SA110310855B1 (ar) 2014-09-16
EP3101028A1 (en) 2016-12-07
AP2012006275A0 (en) 2012-06-30
EA201290319A1 (ru) 2012-12-28
CA2780740A1 (en) 2011-05-19
HRP20170176T1 (hr) 2017-04-07
BR112012011395B1 (pt) 2022-03-03
CA2780740C (en) 2019-08-20
ZA201203516B (en) 2013-01-31
KR101881947B1 (ko) 2018-07-26
HK1176074A1 (en) 2013-07-19
CO6551684A2 (es) 2012-10-31

Similar Documents

Publication Publication Date Title
PL3653150T3 (pl) Narzędzia chirurgiczne ultradźwiękowe
LT2512581T (lt) Intravezikalinio suderinamumo implantuojamas medicininis įtaisas
EP2691036A4 (en) SURGICAL ULTRASOUND INSTRUMENTS
DK2462893T3 (da) Universel scanningsdel til anvendelse på dentalimplantat og dentalimplantat-analoge
CA3287327A1 (en) Extended Use Medical Device
GB2479176B (en) Surgical instrument
BR112012001637A2 (pt) dispositivo médico implantável
DK2658435T3 (da) Integreret dobbelt swept kilde til medicinsk oct afbildning
AP2014007420A0 (en) Integrated portable medical diagnostic system
EP2471437A4 (en) MEDICAL DEVICE
BR112012003844A2 (pt) vacinas de pttv e diagnóstico
EP2481355A4 (en) MEDICAL DEVICE
EP2509526A4 (en) MULTIFIBRE FLEXIBLE SURGICAL PROBE
EP2515972A4 (en) MEDICAL DEVICE
EP2542163A4 (en) SURGICAL INSTRUMENT
EP2564796A4 (en) MEDICAL INSTRUMENT
EP2691034A4 (en) ULTRASONIC SURGICAL INSTRUMENTS
GB0911643D0 (en) Surgical instrument
ZA201203516B (en) The use of an l3 and/or l5 source as a vaccine or as a diagnostic for a parasitic disease
IT1396812B1 (it) Dispositivo per il trasporto di strumenti medicali.
GB2469839B (en) Medical instrument
GB0905594D0 (en) Surgical instrument
GB201016461D0 (en) Medical instrument
GB0908425D0 (en) Medical use
BR112014006593A2 (pt) dispositivo médico para inserção no corpo humano